Effect of a multicomponent intervention in components of metabolic syndrome: a study with overweight/obese low-income school-aged children

This study aimed to investigate the effects of a 12-week multicomponent intervention program in markers of metabolic syndrome and NAFLD in Brazilian overweight/obese low-income school-aged children.MethodsThis quasi-experimental study comprised overweight/obese school-aged children, aged 7 –13 years. The participants were assigned to intervention (n = 17) or control group (n = 18). The multicomponent intervention was developed during 12 weeks, consisting of exercise sessions (twice/week; 1 h), nutritional education sessions (once/month), and parental support (twice/week). The following variables were evaluated: anthropometric measures (height, body weight, waist c ircumference, percentage of body fat); biochemical assays (total cholesterol (TC), triglycerides-TG, high-density lipoprotein-HDL, glucose, aspartate aminotransferase-AST, alanine aminotransferase-ALT), cardiorespiratory fitness, and maturational stage. A cardiovascular disease (CVD) composite z-sco res (percentage of body fat, glucose, AST, ALT, TG, and TC/HDL ratio) was also calculated. General linear models were used for data analysis.ResultsCompared to the control group, intervention group participants decreased percentage of body fat ( Δ − 0.97;p 
Source: Sport Sciences for Health - Category: Sports Medicine Source Type: research

Related Links:

Nonalcoholic fatty liver disease (NAFLD) is estimated to affect up to one-third of the general population, and new therapies are urgently required. Our laboratory previously developed a controlled-release mitochondrial protonophore (CRMP) that is functionally liver-targeted and promotes oxidation of hepatic triglycerides. Although we previously demonstrated that CRMP safely reverses hypertriglyceridemia, fatty liver, hepatic inflammation, and fibrosis in diet-induced rodent models of obesity, there remains a critical need to assess its safety and efficacy in a model highly relevant to humans. Here, we evaluated the impact ...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. Its prevalence is increasing because of obesity, metabolic syndrome or Type 2 Diabetes Mellitus (T2DM). NAFLD can cause liver inflammation and progress to Non-Alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis or Hepatocellular Cancer (HCC). Nevertheless, Cardiovascular Disease (CVD) is the most common cause of morbidity and mortality in NAFLD/NASH patients. Current guidelines suggest the use of p...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research
Abstract BACKGROUND: Obesity is a major risk factor for a variety of diseases such as diabetes, nonalcoholic fatty liver disease, and cardiovascular diseases. Restricting energy intake, or caloric restriction (CR), can reduce body weight and improve metabolic parameters in overweight or obese patients. We previously found that Lingguizhugan decoction (LZD) in combination with CR can effectively lower plasma lipid levels in patients with metabolic syndrome. However, the mechanism underlying CR and LZD treatment is still unclear. AIM: To investigate whether CR and LZD improve metabolic parameters by modulating ...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity, insulin resistance (IR) and the metabolic syndrome (MetS) and is a leading cause of cirrhosis [1,2]. Its global prevalence is 25% [3] and is increasing worldwide [4] accompanied by severe complications particularly in high-risk older obese patients [5]. Thiazolidinediones, statins and vitamin E have been proposed for the management of NAFLD [6,7] together with lifestyle modifications [8], but there is currently no specifically approved medication.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research
Background: Youth-onset type 2 diabetes (T2D) is increasing in many countries, creating large personal and societal burdens. While many primary health-care professionals (HCPs) are aware of the classic symptoms of T2D, there are several other manifestations that could indicate its presence.Summary: This narrative review summarizes information on these symptoms and indicators, focusing on those less well known. The classic symptoms and comorbidities include frequent urination, excessive thirst, metabolic syndrome, and obesity. In addition to these, the presence of dermatological (e.g., acanthosis nigricans, granuloma annula...
Source: Annals of Nutrition and Metabolism - Category: Nutrition Source Type: research
In conclusion, TSF improved lipid accumulation and hepatic steatosis by inducing the AMPK/SIRT1 pathway-mediated autophagy. Introduction Nonalcoholic fatty liver disease (NAFLD) has become a worldwide health concern due to the increased incidence of obesity and diabetes. In addition, NAFLD is closely associated with the risk factors of coronary heart disease, such as metabolic syndrome, diabetes mellitus, and dyslipidemia, which are considered to be the leading causes of death (Wiest et al., 2017). Although our understanding of the pathogenesis of NAFLD has significantly improved, there is still no effective medica...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
In this study, room temperature (RT) of 25°C was considered as control, and RT at 32°C for 8 h per day was set as the HS treatment. After 3 weeks, the intestinal contents of jejunum, ileum, and cecum were harvested to investigate the microbiota composition variations by 16S ribosomal RNA amplicon sequencing. And the weight gain, adipose indices, intestinal morphology, and a certain number of serum biochemical parameters were also measured and analyzed. The results showed the microbial species at different levels differentially enriched in duck jejunum and cecum under HS, while no significant data were observed in i...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Ali Mahzari1, Songpei Li1, Xiu Zhou1,2, Dongli Li2, Sherouk Fouda1, Majid Alhomrani1, Wala Alzahrani1, Stephen R. Robinson1 and Ji-Ming Ye1,2* 1Lipid Biology and Metabolic Disease Laboratory, School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia 2School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China The present study investigated the effects of matrine on non-alcoholic steatohepatitis (NASH) in mice induced by a methionine choline-deficient (MCD) diet and the mechanism involved. The study was performed in C57B/6J mice fed a MCD diet for 6 weeks to induce NAS...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
(CNN) — Whether you eat breakfast might be linked with your risk of dying early from cardiovascular disease, according to a new study. Skipping breakfast was significantly associated with an increased risk of cardiovascular-related death, especially stroke-related death, in the study published in the Journal of the American College of Cardiology on Monday. After a person’s age, sex, race, socioeconomic status, diet, lifestyle, body mass index and disease status were taken into account, the study found that those who never had breakfast had a 87% higher risk of cardiovascular mortality compared with people who h...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News CNN Heart Disease Source Type: news
In conclusion, FGF21 belongs to a promising class of cytokines that are induced in response to stress and that can be used as a drug, drug target, or through a biomarker, depending on the physio-pathological context. All these findings will become clear when FGF21 will be used as a therapeutic molecule, exploiting the beneficial effects of FGF21 for treating metabolic disease or when it will be blocked to ameliorate disease progression and the onset of disease. Author Contributions CT and MS wrote the manuscript. VR contributed to the discussion. Funding This work was supported from the AFM-Telethon (19524), Italian Mi...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
More News: Brazil Health | Cardiology | Cardiovascular | Children | Cholesterol | Eating Disorders & Weight Management | Education | Fatty Liver Disease (FLD) | Heart | Liver | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Obesity | Sports Medicine | Study | Universities & Medical Training | Urology & Nephrology